Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(10):1686–1688. doi: 10.1038/bjc.1998.278

Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.

H Kunitoh 1, N Saijo 1, K Furuse 1, K Noda 1, M Ogawa 1
PMCID: PMC2150075  PMID: 9635850

Abstract

We retrospectively analysed neuromuscular toxicity associated with paclitaxel 210 mg m(-2) given by 3-h infusion in 247 patients. The severity correlated significantly with total cumulative dose, but could not be predicted by the pretreatment clinical variables or by pharmacokinetic parameters. The toxicity tended to occur in early treatment cycles.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chaudhry V., Rowinsky E. K., Sartorius S. E., Donehower R. C., Cornblath D. R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994 Mar;35(3):304–311. doi: 10.1002/ana.410350310. [DOI] [PubMed] [Google Scholar]
  2. Eisenhauer E. A., ten Bokkel Huinink W. W., Swenerton K. D., Gianni L., Myles J., van der Burg M. E., Kerr I., Vermorken J. B., Buser K., Colombo N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994 Dec;12(12):2654–2666. doi: 10.1200/JCO.1994.12.12.2654. [DOI] [PubMed] [Google Scholar]
  3. Gianni L., Kearns C. M., Giani A., Capri G., Viganó L., Lacatelli A., Bonadonna G., Egorin M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995 Jan;13(1):180–190. doi: 10.1200/JCO.1995.13.1.180. [DOI] [PubMed] [Google Scholar]
  4. Gianni L. Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol. 1995 Nov;6(9):861–863. doi: 10.1093/oxfordjournals.annonc.a059349. [DOI] [PubMed] [Google Scholar]
  5. Ohtsu T., Sasaki Y., Tamura T., Miyata Y., Nakanomyo H., Nishiwaki Y., Saijo N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res. 1995 Jun;1(6):599–606. [PubMed] [Google Scholar]
  6. Postma T. J., Vermorken J. B., Liefting A. J., Pinedo H. M., Heimans J. J. Paclitaxel-induced neuropathy. Ann Oncol. 1995 May;6(5):489–494. doi: 10.1093/oxfordjournals.annonc.a059220. [DOI] [PubMed] [Google Scholar]
  7. Schiller J. H., Storer B., Tutsch K., Arzoomanian R., Alberti D., Feierabend C., Spriggs D. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994 Feb;12(2):241–248. doi: 10.1200/JCO.1994.12.2.241. [DOI] [PubMed] [Google Scholar]
  8. Tamura T., Sasaki Y., Eguchi K., Shinkai T., Ohe Y., Nishio M., Kunikane H., Arioka H., Karato A., Omatsu H. Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. Jpn J Cancer Res. 1994 Oct;85(10):1057–1062. doi: 10.1111/j.1349-7006.1994.tb02906.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Tamura T., Sasaki Y., Nishiwaki Y., Saijo N. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res. 1995 Dec;86(12):1203–1209. doi: 10.1111/j.1349-7006.1995.tb03316.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Wiernik P. H., Schwartz E. L., Einzig A., Strauman J. J., Lipton R. B., Dutcher J. P. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987 Aug;5(8):1232–1239. doi: 10.1200/JCO.1987.5.8.1232. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES